(Rewrites paragraph 1 with deal value, adds details from
paragraph 2)
BENGALURU, March 14 (Reuters) - Biopharmaceutical
company Biocon's BION.NS unit Biocon Biologics will sell its
Indian branded formulations to Eris Lifesciences ERIS.NS in a
deal worth 12.42 billion rupees ($150 million), the companies
said in separate exchange filings on Thursday.
The transaction is expected to close by April 15, 2024,
Biocon said. As a part of the deal, it signed a 10-year supply
agreement with Eris, it added.
The deal includes the acquisition of two insulin brands,
Basalog and Insugen, which Eris said will help its diabetes
treatment franchise reach 10 billion rupees in revenue, without
specifying a timeline.
With the purchase of the branded formulations business, Eris
will enter the oncology and critical care segments, it said.
($1 = 82.8170 Indian rupees)
(Reporting by Varun Vyas in Bengaluru; Editing by Janane
Venkatraman and Sonia Cheema
)
((varunvyas.hebbalalu@thomsonreuters.com;))